Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis

@article{Moses2008ManagingAE,
  title={Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis},
  author={H. Moses and D. Brandes},
  journal={Current Medical Research and Opinion},
  year={2008},
  volume={24},
  pages={2679 - 2690}
}
ABSTRACT Background: First-line agents approved in the United States for treatment of relapsing multiple sclerosis (MS) include intramuscular interferon beta (IFNβ)-1a, subcutaneous (SC) IFNβ-1a, SC IFNβ-1b, and SC glatiramer acetate. Intravenous mitoxantrone is the only agent approved for secondary progressive MS, progressive relapsing MS, and worsening relapsing MS. Intravenous natalizumab is approved for relapsing forms of MS generally in patients who have an inadequate response to, or are… Expand
Best Practices in Skin Care for the Multiple Sclerosis Patient Receiving Injectable Therapies
TLDR
Nurses involved in the care of patients with MS should be knowledgeable about the potential ISRs associated with disease-modifying therapies such as beta-interferons, glatiramer acetate, and natalizumab. Expand
Management of flu-like syndrome with cetirizine in patients with relapsing-remitting multiple sclerosis during therapy with interferon beta: Results of a randomized, cross-over, placebo-controlled pilot study
TLDR
The addition of cetirizine to the standard of care for IFN β-induced FLS in patients with RRMS does not seem to provide significant benefits compared with placebo, and further effort is required to understand the mechanisms underlying IFNβ- induced FLS. Expand
Nurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.
TLDR
Prevention and mitigation strategies, in addition to effective patient education, will help to reduce the incidence of FLS secondary to IFNβ therapy, improve patient medication adherence, and positively affect long-term clinical outcomes. Expand
Injectable multiple sclerosis medications: a patient survey of factors associated with injection-site reactions.
TLDR
For all DMTs injection-site massage and avoidance of sensitive sites were the most frequently used strategies to minimize ISRs, with IM IFNβ-1a causing significantly fewer mild, moderate, or severe ISRs than the other therapies. Expand
Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study
TLDR
IFN-β1a evening injections in the first 8 weeks of treatment led to an improvement in FLS; when continuing therapy, time of administration could be decided according to patient’s lifestyle and preference. Expand
Alemtuzumab in the treatment of relapsing–remitting multiple sclerosis
  • E. Fox
  • Medicine
  • Expert review of neurotherapeutics
  • 2010
TLDR
Enrollment in two pivotal Phase III clinical trials of alemtuzumab in MS is now complete and multiple insights have been made into the nature of autoimmunity in general based on the clinical response to this monoclonal antibody. Expand
Cladribine tablets added to IFN-β in active relapsing MS
TLDR
This study provides Class I evidence that for patients with active relapsing MS despite IFn-β treatment, cladribine tablets added to IFN-β reduced relapses and MRI lesion activity over 96 weeks and increased the incidence of lymphopenia. Expand
Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation
TLDR
Dose titration during initiation of IM IFNβ-1a reduces FLS severity and incidence in healthy volunteers compared with no titration, and safety profiles for both titration regimens were consistent with the current IM IFnβ- 1a label. Expand
Management of IFN-beta-induced flu-like symptoms with Chinese herbal medicine in a patient with multiple sclerosis: A case report.
TLDR
Chinese herbal medicine, associated with Salvia miltiorrhiza, Ligusticum chuanxiong, Angelica dahurica and Polygonum multiflorum Thunb, is an effective prescription to ameliorate such symptoms and signs in patients with MS. Expand
Management of multiple sclerosis and the integration of related specialty pharmacy programs within health systems.
  • M. Habibi, Huda-Marie Kuttab
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2016
TLDR
Good compliance, compliance with the associated REMS program, and timely access to these drugs may positively influence patient care and outcomes and provide an opportunity for the health-system pharmacists to have a active role in caring for these patients. Expand
...
1
2
...

References

SHOWING 1-10 OF 90 REFERENCES
Considerations in the treatment of relapsing-remitting multiple sclerosis
TLDR
Several currently marketed treatments, including IV immunoglobulin, methotrexate, and azathioprine, are being evaluated as treatments for RRMS in combination with the approved therapies, and Investigational compounds, including oral formulations of glatiramer acetate and interferon, are in various stages of development. Expand
Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis.
In separate clinical trials, two preparations of recombinant interferon (IFN)-beta, IFN beta-1a and IFN beta-1b, reduced exacerbation rates in relapsing-remitting multiple sclerosis (RR-MS). Further,Expand
Disease-Modifying Therapy in Multiple Sclerosis: Strategies For Optimizing Management
TLDR
An assessment and intervention instrument is formulated that can be used in the clinic and by telephone to enhance compliance and minimize adverse events and serve to optimize the management of patients and effectively meet the challenges that arise during the course of treatment. Expand
Managing the Adverse Effects of Interferon-β Therapy in Multiple Sclerosis
TLDR
If recommendations are followed, adverse effects related to interferon-β may be substantially reduced in the majority of patients, based on a literature review and personal experience. Expand
Management of patients receiving interferon beta-1b for multiple sclerosis
Article abstract-Results of a double-blind, placebo-controlled study in ambulatory patients with relapsing-remitting MS showed that interferon beta-1b reduced the rate of exacerbations by one-thirdExpand
Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
TLDR
Treatment with interferon β-1b is the first treatment to show a therapeutic effect in patients with SP-MS, and delayed progression for 9–12 months in a study period of 2–3 years. Expand
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
TLDR
Interferon beta‐ la had a significant beneficial impact in relapsing multiple sclerosis patients by reducing the accumulation of permanent physical disability, exacerbation frequency, and disease activity measured by gadolinium‐enhanced lesions on brain magnetic resonance images. Expand
Strategies for managing the side effects of treatments for multiple sclerosis
TLDR
Physicians must be aware of appropriate laboratory monitoring schedules to prevent serious toxicities and to become familiar with less serious but more common side effects that often threaten patient compliance. Expand
Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis
TLDR
Subcutaneous interferon β-1a is an effective treatment for relapsing/remitting MS in terms of relapse rate, defined disability, and all MRI outcome measures in a dose-related manner, and it is well tolerated. Expand
Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b.
TLDR
It is concluded that a vasculitic-like cutaneous reaction to interferon beta-1b may occur long after institution of therapy in some MS patients. Expand
...
1
2
3
4
5
...